Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation
| Autor: | S. Darwish Murad, Thijmen Visseren |
|---|---|
| Přispěvatelé: | Gastroenterology & Hepatology |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Cholangitis Sclerosing Autoimmune hepatitis 030230 surgery Liver transplantation Chronic liver disease Gastroenterology Primary sclerosing cholangitis 03 medical and health sciences 0302 clinical medicine SDG 3 - Good Health and Well-being Recurrence Risk Factors Internal medicine medicine Humans Hepatitis business.industry Liver Cirrhosis Biliary Incidence (epidemiology) medicine.disease digestive system diseases Liver Transplantation Transplantation Hepatitis Autoimmune Auto immune hepatitis 030211 gastroenterology & hepatology business |
| Zdroj: | Best Practice & Research in Clinical Gastroenterology, 31(2), 187-198. Bailliere Tindall Ltd |
| ISSN: | 1521-6918 |
| Popis: | Liver transplantation is a well-accepted treatment for decompensated chronic liver disease due to primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and auto-immune hepatitis (AIH). Survival after liver transplantation is generally good with 1 and 5-year survival rates around 90% and 70-85%. After transplantation, however, these diseases recur in 8.6-27% (rPSC), 10.9-42.3% (rPBC) and 7-42% (rAIH), and this poses significant challenges in terms of management and graft outcome in these patients. In this review we discuss the incidence, clinical presentation, challenges in diagnosis, reported risk factors and impact on post-transplant outcomes of recurrence of PSC, PBC and AIH after liver transplantation. We also discuss some of the limitations of current investigations and formulate idea's for future research objectives. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect